TNI BioTech, Inc. (TNIB) is focused on utilizing patented immunotherapy to activate and mobilize the body's immune system to combat fatal diseases. The company's products and technologies improve the treatment and diagnosis of cancer, infections such as HIV/AIDS, and autoimmune diseases. Future initiatives include treatment for multiple sclerosis, herpes viral infections, and other conditions that result in altered-immune response.
The company's product portfolio currently includes IRT-101, an active immunotherapy that works by activating a patient's immune system against infectious diseases and tumor cells; IRT-102, an adaptive immunotherapy that works by isolating and enriching a patient's own immune cells; and IRT-103, an active immunotherapy that works by activating a patient's immune system against HIV/AIDS and tumor cells.
Leveraging the advantages of today's cutting-edge treatment options, the company aims to meet the growing demand for quality healthcare with safer, more effective radiation therapy; new-targeted drug therapies; and minimally invasive surgical alternatives around the world. TNI BioTech most recently signed a letter of intent to open clinics in Africa that will provide advanced treatment for cancer, HIV/AIDS, and autoimmune diseases.
The company plans to continue clinical trials in China during 2012 and 2013, and anticipates starting trials in the United States by early 2013.The company is also in negotiations to acquire a number of other immunotherapy products, patents, and therapies. Led by a management team with decades of experience and solid business plan, TNI BioTech is poised to improve healthcare with active and adaptive forms of improved immunotherapies.
See http://www.tnibiotech.com for more information.
Contact: Global Investment Media
|Shares Outstanding ||86,371,347 ||a/o May 12, 2014 |
TNI BioTech Products
IRT-101 is an active immunotherapy that works by activating a patient's immune system against infectious diseases and tumor cells. This is accomplished by increasing the number of T cells and NK cells, NKT and Gammadelta T cells that destroy infective organisms and tumor cells while simultaneously inhibiting Treg cells.
IRT-102 is an adaptive immunotherapy that works by isolating and enriching a patient's own immune cells and following an enriching external incubation are transfused back into the patient thereby providing the patient with a passive immunity containing large amounts of auto-amplified immune cells that combat cancer cells.
IRT-103 is an active immunotherapy that works by activating a patient's immune system against HIV/AIDS and tumor cells. This is accomplished by activating the enkephalin receptor system resulting in increased number of T cells and NK cells that destroy infective organisms and tumor cells.
However, since any condition that results in an altered-immune response is a potential target for investigation. The Company intends to investigate the following valuable candidates:
Autoimmune states such as rheumatoid arthritis and multiple sclerosis.
As an adjuvant to vaccines in the protection from getting infectious diseases
In patients undergoing chemotherapy or radiation treatments in surgery
In wound healing, herpes and shingles in the elderly.
In clinical trials the evidence is significant that LDN/MENK stimulates the immune system and that it is effective in the treatment of some immune-suppressed diseases. The treatment modality has been demonstrated to be effective while avoiding certain deleterious effects on the body, as is often the case with traditional chemotherapy. The costs are reasonable, making this an attractive complement for a large number of cancer patients